Innovative biomarkers are required to manage type 2 @entity6 @entity1 (T2DM). We focused our study on @entity17655 and @entity29087 levels, as biomarkers of endothelial function and @entity32 . MiRNAs levels were measured in plasma from 107 healthy subjects ( @entity8982 ) and 193 @entity6 @entity1 (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications. When @entity6 complication were analysed as a whole, @entity17655 and @entity29087 levels declined significantly from @entity8982 to T2DM NC and T2DM C @entity1 . When miRNAs levels were related to specific complications, significantly higher @entity29087 levels (0.46    0.44 vs. 0.26    0.33, p < 0.001) and significant lower @entity17655 levels (0.21    0.21 vs. 0.28    0.22, p = 0.032) were found in T2DM with previous major @entity65 (MACE) vs. all the others T2DM @entity1 . To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 @entity8982 , 15 T2DM NC and 15 T2DM @entity1 with MACE. CACs from T2DM @entity1 expressed higher @entity29087 and lower @entity17655 levels than CACs from @entity8982 . Furthermore, CACs from T2DM + MACE showed the highest levels of @entity29087 . Circulating @entity29087 and @entity17655 emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.

XXXX and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity17655 :: ('100302148', 'Gene') :: ['miR-126-3p'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity29087 :: ('406997', 'Gene') :: ['miR-21-5p'] @entity8982 :: ('799', 'Gene') :: ['CTR'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular events']
@entity29087 :: (406997,Gene) :: ['MiR-21-5p']
